New data, Phase 3 trials, and rising demand are fueling massive
opportunities. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

_Prefer to view this content on our website? Click here.
[[link removed]]
_

-------------------------

Dear Fellow Investor,

THREE OF THE TOP OBESITY STOCKS TO BUY AND HOLD TODAY

Obesity and metabolic disorders remain two of the most pressing global
health challenges, and two of the most lucrative opportunities in
modern biopharmaceuticals. With worldwide obesity rates continuing to
climb, analysts expect the market for weight-loss drugs to surge to
$100 BILLION OR MORE BY THE EARLY 2030S. Some estimates even suggest
the total addressable market could stretch beyond $150 BILLION, making
it one of the largest and fastest-growing segments in all of
healthcare.

That’s why we’ve been pounding the table on obesity-drug
developers for the last several years. What started as a niche
opportunity has quickly become one of Wall Street’s biggest
megatrends, one that has already produced enormous winners and could
continue fueling substantial returns in the years ahead.

We frequently highlight VIKING THERAPEUTICS (SYM: VKTX) and STRUCTURE
THERAPEUTICS (SYM: GPCR) as two of the most compelling emerging
players. But now, another heavyweight deserves a spot on the list: ELI
LILLY (SYM: LLY), a company rapidly solidifying its dominance in the
obesity and diabetes markets.

Below is a deeper look at three of the top stocks that long-term
investors may want to buy, hold, and let compound as the obesity-drug
industry enters its next major growth phase.

-------------------------

COMPANY: ELI LILLY (SYM: LLY)
A MARKET LEADER WITH ROOM TO RUN

Eli Lilly has become one of the biggest winners in the GLP-1 space,
thanks to its obesity and diabetes therapies ZEPBOUND and MOUNJARO,
both of which continue to exceed expectations. With demand for GLP-1
treatments soaring worldwide, analysts have consistently raised their
outlook for Lilly, and the latest revisions are among the most bullish
yet.

Bank of America recently reiterated a BUY rating on Eli Lilly and
raised its price target from $950 TO $1,286, citing the company’s
commanding lead in next-generation metabolic treatments. The firm
notes that Lilly remains firmly in first place in the obesity and
diabetes categories, with a robust GLP-1 franchise and a development
roadmap that is years ahead of many competitors.

One of the most exciting developments is the company’s progress on
its new _oral_ obesity medication. While injections dominate the
market today, oral GLP-1–based therapies could dramatically expand
global adoption. Bank of America now believes Eli Lilly may launch its
new oral obesity drug in early 2026, rather than later in the year, an
acceleration that could unlock billions in additional market
opportunity.

Given that obesity treatment is quickly becoming one of the most
competitive pharmaceutical battlegrounds, Lilly’s momentum is
impossible to ignore. The company’s scale, manufacturing
capabilities, and broad clinical pipeline give it a formidable
advantage that smaller biotech firms will struggle to match.

Bottom line: ELI LILLY REMAINS ONE OF THE PREMIER LONG-TERM PLAYS IN
THE GLOBAL OBESITY-DRUG REVOLUTION.

-------------------------

_Edge on the Street_

A TINY BIOTECH JUST POSTED 10× STRONGER CANCER RESULTS
[[link removed]]

[BIOTECH STOCKS]
[[link removed]]

 

 

 

 

Early studies show this breakthrough delivery platform would make
cancer treatments safer and more powerful. Now, with Big Pharma
watching closely, investors are starting to take notice of what could
be the next major biotech story.

DISCOVER THE COMPANY BEHIND THIS BREAKTHROUGH
[[link removed]]

-------------------------

COMPANY: VIKING THERAPEUTICS (SYM: VKTX)
A HIGH-GROWTH CONTENDER WITH BREAKTHROUGH POTENTIAL

While Eli Lilly is the large-cap powerhouse of the obesity market,
VIKING THERAPEUTICS is one of the most intriguing emerging players,
one that continues to generate strong clinical results and heightened
investor interest.

Trading at around $34.94, VKTX has already seen periods of explosive
upside and could do so again if its obesity trials continue to move in
the right direction. The company recently initiated its VANQUISH PHASE
3 CLINICAL PROGRAM for VK2735, a dual agonist targeting both the GLP-1
and GIP receptors. This dual-agonist approach is especially exciting
because early data from other companies suggest that dual or
tri-agonists could deliver superior weight-loss outcomes compared to
single-pathway drugs.

Viking is pursuing both ORAL AND SUBCUTANEOUS formulations of VK2735,
giving it multiple shots on goal in a market expected to remain
underserved for years. The company is aggressively broadening its
development pipeline, with additional studies planned that could
enhance the drug’s long-term positioning.

According to CEO BRIAN LIAN, PH.D., Viking is making progress not only
on the flagship Phase 3 study, but also on plans to launch a clinical
trial evaluating a MONTHLY MAINTENANCE REGIMEN, a major convenience
advantage if successful. In addition, Viking expects to release
results from its PHASE 2 VENTURE-ORAL DOSING STUDY in the second half
of this year, which could serve as a major catalyst.

There’s also the ongoing takeover speculation.

Rumors continue to circulate that major pharmaceutical companies,
INCLUDING PFIZER, which has openly stated its interest in expanding
its obesity pipeline, could potentially acquire Viking Therapeutics.
Pfizer CEO ALBERT BOURLA has repeatedly said the company is evaluating
strategic deals to strengthen its obesity-treatment portfolio after
setbacks with its own GLP-1 program.

With promising clinical data, accelerating trial progress, and the
ever-present possibility of M&A, VKTX remains one of the most
explosive opportunities in the obesity-drug space.

-------------------------

_Banyan Hill_

The Comeback of the Century:
Wall Street Wrote Him Off… But Elon’s $3 Trillion Comeback Could
Begin Soon
[elon]
[[link removed]]

Elon Musk was declared washed up and finished. But any day now, he
could unveil a new technology that outshines Tesla, SpaceX, even
PayPal… a breakthrough big enough to solve America’s toughest
problem, make President Trump a hero to the Western World… and spark
a $3 trillion boom. Early investors could see massive gains. DETAILS
HERE.
[[link removed]]

-------------------------

COMPANY: STRUCTURE THERAPEUTICS (SYM: GPCR)
STRONG DATA AND A BIG CATALYST ON THE HORIZON

Another major contender in the race for obesity-drug dominance is
STRUCTURE THERAPEUTICS, a company that continues to impress with both
its clinical results and development speed.

GPCR recently announced POSITIVE TOPLINE DATA from its PHASE 2A
OBESITY STUDY of GSBR-1290, an oral small-molecule GLP-1 receptor
agonist. According to the company, the study demonstrated a CLINICALLY
MEANINGFUL AND STATISTICALLY SIGNIFICANT PLACEBO-ADJUSTED MEAN WEIGHT
LOSS OF 6.2% AT JUST 12 WEEKS, a highly encouraging result for an
early-stage oral candidate.

What makes GSBR-1290 particularly exciting is that it aims to deliver
GLP-1–like results WITHOUT INJECTIONS, positioning it as a direct
competitor to the oral programs being developed by Eli Lilly and Novo
Nordisk. While competition will be fierce, the size of the global
obesity market is exceptionally large, big enough to support multiple
winners.

Structure Therapeutics is now preparing to initiate a 36-WEEK PHASE 2B
STUDY of GSBR-1290 in the fourth quarter of this year. If the
longer-duration study continues to show strong efficacy and safety,
GPCR shares could climb aggressively higher, especially with major
pharmaceutical companies hunting for oral obesity-drug assets.

Because oral GLP-1 therapies are viewed as the next major frontier in
metabolic disease treatment, companies like Structure Therapeutics
could be extremely well-positioned as the market evolves.

-------------------------

_Stansberry Research_
A BREAKTHROUGH SET TO RESHAPE AMERICA
[[link removed]]_

_A quiet technological shift is racing ahead - and most investors are
completely unprepared. This breakthrough could mint new millionaires
as Silicon Valley and Washington scramble to back it. But if you're
not positioned before Jan. 1, you may miss the entire early wave.
CLICK NOW BEFORE THE WINDOW CLOSES.
[[link removed]]

-------------------------

_Are there any other healthcare/biotech stocks you're buying right
now? What other sectors of the market are you currently interested in?
Hit "reply" to this email and let us know your thoughts!_

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of Defence Therapeutics (OTC: DTCFF). The compensation consists of up
to $5,500 and was received/will be received from i2i Marketing Group.

This communication should not be considered as an endorsement of the
securities of adviser Defence Therapeutics (OTC: DTCFF) and we are not
responsible for any errors or omissions in any information provided
about the securities of Defence Therapeutics (OTC: DTCFF) by Edge on
the Street or i2i Merketing Group.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 12/03/2025.

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]